Denali Therapeutics announced on Friday that it had been informed by its strategic partner Sanofi of the failure of a Phase 2 clinical trial in the treatment of amyotrophic lateral sclerosis (ALS).

According to the biopharmaceutical company, SAR443820/DNL788 did not meet its primary efficacy endpoint in the study, which consisted of an improvement in functional scores.

Denali adds that Sanofi plans to present the detailed results of the study at an upcoming scientific congress.

The Phase 2 study involving SAR443820/DNL788, an oral small molecule that crosses the blood-brain barrier, is nevertheless set to continue as planned in multiple sclerosis.

Sanofi and Denali Therapeutics had announced in 2018 their intention to jointly develop drugs for the treatment of neurological and inflammatory diseases.

Listed on the Paris Bourse, Sanofi shares were down 0.6% after this announcement. On Wall Street, Denali shares fell by over 7%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.